iQIYI Inc (IQ) Stock News

Enphase Energy announced production shipments of its IQ9S-3P Commercial Microinverter, featuring advanced GaN technology with 548 VA output capacity and support for solar panels up to 770 W. The product is designed for three-phase 480Y/277 V commercial grid configurations and achieves 97.5% CEC weighted efficiency. Safe harbor orders are open until July 4, 2026, to help customers secure equipment ahead of federal tax credit deadlines. The microinverter is manufactured in U.S. facilities and may qualify for domestic content bonus tax credits.

IQSTEL Inc. (NASDAQ: IQST) announced a share repurchase program authorizing the repurchase of up to 1,000,000 shares, funded by cash dividends from subsidiary QXTEL. The Board believes the current market valuation does not reflect the company's operational scale, asset base, and growth prospects. The announcement comes alongside a binding MOU to acquire a 51% stake in Ultranet Telecom Group, expected to increase net income by approximately 4X and contribute $4.5 million in annual net income.

VanEck Bitcoin ETF (HODL) offers concentrated exposure to bitcoin with $1.1 billion in assets, while Hashdex Nasdaq Crypto Index US ETF (NCIQ) provides diversified exposure to both bitcoin and ether with $96.1 million in assets. Both funds charge 0.25% expense ratios and use spot assets rather than derivatives. The choice depends on whether investors prefer bitcoin's simplicity and institutional credibility or broader digital asset ecosystem exposure.

Global Clean Energy, Inc. (GCEI) announced the launch of ResilientIQ™, an AI platform designed for emergency management professionals to access operational guidance for disaster response planning. The platform is now in active market demonstrations and commercial outreach with government agencies and institutional stakeholders, marking a transition from development to commercialization.

Royal Philips announced FDA 510(k) clearance for Elevate Plus, an AI-powered software suite for its EPIQ Elite and Affiniti ultrasound systems. The technology features automated measurement capabilities, workflow automation, and AI decision support for lesion classification, designed to reduce scanning time by up to 30% while maintaining clinical accuracy and helping healthcare providers manage growing demand.

Ipsen presented new clinical data on IQIRVO (elafibranor) at the EASL congress, demonstrating significant improvements in alkaline phosphatase (ALP) reduction, fatigue, and pruritus in primary biliary cholangitis (PBC) patients. Real-world data showed 59% of patients achieved ALP normalization at 6 months, while 67% of patients with moderate-to-severe fatigue showed clinically significant improvements compared to 31% on placebo at 52 weeks.

Ipsen announced late-breaking results from the ELATIVE Phase III trial and real-world studies showing IQIRVO (elafibranor) demonstrated clinically meaningful improvements in fatigue, with 67% of patients achieving improvement versus 31% on placebo at Week 52. Real-world data showed 59% of patients achieved ALP normalization at 6 months, and the Phase IV ELFINITY study confirmed rapid ALP reductions and favorable tolerability in routine clinical practice.

NIQ Global Intelligence CEO James Peck purchased 118,625 shares worth approximately $1 million at $8.43 per share on May 18, 2026, signaling bullish sentiment despite the stock declining 55.5% over the prior year. The company reported strong 11% revenue growth in Q1 2026 but swung to an operating loss due to $64.9 million in restructuring costs. With expectations for $70 million in cost savings this year and a price-to-sales ratio below one, the insider buy suggests confidence in future financial improvement.

iQSTEL reported Q1 2026 revenue of $97.9 million, up 70% year-over-year, driven by organic growth and GlobeTopper integration. The company is transitioning from a telecom provider to a global digital services distribution platform, launching high-margin offerings in AI, fintech, cybersecurity, and digital health with expected gross margins of 25-40%. Management maintains a $430 million 2026 revenue target and long-term $1 billion vision, while noting the stock trades at $1.30 versus a book value of nearly $3 per share.

Company Expands Global Commercial Platform to Commercialize AI, Fintech , Cybersecurity, Digital Health, and Advanced Digital Services NEW YORK , May 21, 2026 /PRNewswire/ -- IQSTEL Inc. (NASDAQ: IQST ), a rapidly growing global telecommunications and technology company, on May 20, 2026 reported its financial results for the first quarter ended March 31, 2026, highlighting strong revenue growth and a strategic transformation that positions the Company as a powerful global distribution channel for next-generation digital services. Financial Performance Overview IQSTEL continued to execute on its growth strategy, expanding its commercial reach and strengthening its position as a platform capable of scaling digital services globally. Metric Q1 2026 Q1 2025 Growth Revenue $97.9 million $57.6 million +69.9 % Gross Profit $2.08 million $1.93 million +7.8 % Gross profit reflects the Company's current ... Full story available on Benzinga.com

SALT LAKE CITY, May 20, 2026 (GLOBE NEWSWIRE) -- OMNIQ Corp (OTCMTS: OMQS or "OMNIQ" or "the Company") today announced its financial results for the first quarter 2026. The Company reported $7.7 million in quarterly revenue as well as a gross profit increase of 3.3 percent year over year. The Company continues to implement its product focus and cost-reduction strategy designed to increase revenue & footprint, strengthen profitability, and support long-term operational efficiency. Financial Highlights For the three months ended March 31, 2026, compared to the same period in 2025: Revenue was $7.68 million, compared to $7.98 million in the prior-year period. Gross profit increased to $2.255 million, compared to $2.184 million last year. Loss from operations was ($1.2 million), compared to ($425,000) in the prior-year period. Net loss per share improved to ($0.11), compared to ($0.19) last year. Revenue for the three months ended March 31, 2026, was $7.68 million, compared to $7.98 million for the same period in 2025. While revenue was slightly lower year over year, the Company continued to maintain a strong presence across its core markets and strategic deployments, and at the same time continued implementing products focused on serving end customers Gross profit increased to $2.255 million for the quarter, compared to $2.184 million in the prior year period. The improvement reflects continued focus on operational execution, project mix, and higher-margin opportunities across the business. Loss from operations for the quarter was ($1.2 million), compared to ($425,000) in the first quarter of 2025. Operating results reflected continued investments in technology development, operational infrastructure, and strategic business initiatives designed to support future growth. Net loss per share improved to ($0.11) for the three months ended March 31, 2026, compared to ($0.

EnsembleIQ's DSN launched the #FillHealthCareGaps campaign to highlight how community pharmacies and pharmacists can address the projected shortage of 80,000 primary care physicians by 2030. The campaign includes a website, video, and LinkedIn initiative supported by major retailers including CVS Health, Walmart, Kroger Health, Giant Eagle, and Ahold Delhaize USA, emphasizing that nine in ten Americans live within five miles of a pharmacy.

IQIYI Inc.   (NASDAQ: IQ )  on Monday reported first-quarter results  broadly in line with expectations. Management's guidance reflects a deceleration in the year-over-year revenue decline, according to Benchmark. The IQIYI Analyst: Analyst Fawne Jiang reiterated a Hold rating on the stock. The IQIYI Thesis: The key takeaway from the print is the company's "accelerating strategic pivot toward AI-driven production and a more decentralized content ecosystem," Jiang said in the note. Check out other analyst stock ratings . The Q1 Results: IQIYI's total revenue contracted 13% year-on-year to RMB 6.2 billion but came in-line with consensus estimates, with continued weakness across major segments, the analyst stated. He added that: Although membership services declined 5% year-on-year, the company reported sequential growth, driven by a strong performance from premium titles like The Punishment and Pursuit of Jade. Advertising revenue fell 7% year-on-year. Content distribution revenue shrank 43% year-on-year. IQIYI's profitability deteriorated sequentially, while the ... Full story available on Benzinga.com

Nanobiotix announced early results from the Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer developed in collaboration with Johnson & Johnson, in patients with stage 3 inoperable non-small cell lung cancer. The study showed promising efficacy with an 85.7% overall response rate and 57.1% complete response rate in 7 patients who completed treatment, compared to less than 5% complete response rates with current standard of care.

Motley Fool contributor Jason Hall argues that emotional resilience and tolerance for volatility are more important than intelligence for successful stock market investing. Using Amazon and Coca-Cola as examples, he demonstrates why even highly intelligent investors can make significant mistakes and why the ability to stomach market fluctuations is crucial for identifying and holding onto winning stocks.

IQSTEL shares surged 31% in after-hours trading following a strategic update. The company reported 2025 revenue of $316.9 million (11% YoY growth) and expects to reach net profitability within 12 months. Despite missing Q4 earnings estimates, management highlighted an inflection point with high-margin service expansion and targets $1 billion in revenue within 24 months. The platform reaches 2.3 bi